Literature DB >> 2590858

Papillary carcinoma of the thyroid: additional evidence in support of a familial component.

D K Fischer1, M D Groves, S J Thomas, P C Johnson.   

Abstract

Although a higher incidence of medullary carcinoma of the thyroid is well known to occur in families with syndromes of multiple endocrine neoplasia (MEN II and III), an epidemiologic familial component has only very rarely been ascribed to papillary carcinoma. In this report we describe a mother and daughter presenting with neck masses at an early age and subsequently found to have metastatic papillary thyroid carcinoma documented on pathology following thyroidectomy. The occurrence of the neoplasm at an advanced stage in closely related individuals early in life suggests that underlying genetic factors may predispose to this malignancy. Familial papillary carcinoma of the thyroid may have a hereditary basis independent of its association with the syndromes of multiple polyposis and of multiple hamartomas, and thus may represent a new entity with characteristics which distinguish it as a distinct subset of the more common disease.

Entities:  

Mesh:

Year:  1989        PMID: 2590858     DOI: 10.3109/07357908909039857

Source DB:  PubMed          Journal:  Cancer Invest        ISSN: 0735-7907            Impact factor:   2.176


  3 in total

Review 1.  An evidence-based approach to familial nonmedullary thyroid cancer: screening, clinical management, and follow-up.

Authors:  Rebecca S Sippel; Nadine R Caron; Orlo H Clark
Journal:  World J Surg       Date:  2007-05       Impact factor: 3.352

2.  Parental cancer and risk of papillary and follicular thyroid carcinoma.

Authors:  M R Galanti; A Ekbom; L Grimelius; J Yuen
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

3.  Papillary thyroid carcinoma: 6 cases from 2 families with associated lymphocytic thyroiditis harbouring RET/PTC rearrangements.

Authors:  C Mechler; A Bounacer; H Suarez; M Saint Frison; C Magois; G Aillet; A Gaulier
Journal:  Br J Cancer       Date:  2001-12-14       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.